Since most of the mutations that accumulate within a tumor cell are unique, such approaches require a high level of individualization, coupled to sophisticated methods like whole genome sequencing and downstream in silico prediction of MHC-binders [109,114]. This evidence concerns the gene HLA-C and neoplasm.